Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents
Aim. To carry out cost-effectiveness analysis of treatment options for type 2 diabetes using different groups of medicines, to prognosticate late diabeticcomplications and the cost of their management. Materials and methods. A total of 3678 DM2 patients (with mean HbAc1 level 9.3%) were examined i...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2010-03-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6024 |
| _version_ | 1797255278072168448 |
|---|---|
| author | Ivan Ivanovich Dedov Marina Vladimirovna Shestakova Yury Ivanovich Suntsov Roza Imailovna Yagudina Ivan Sergeevich Krysanov Andrey Yur'evich Kulikov Evgenia Evgen'evna Arinina |
| author_facet | Ivan Ivanovich Dedov Marina Vladimirovna Shestakova Yury Ivanovich Suntsov Roza Imailovna Yagudina Ivan Sergeevich Krysanov Andrey Yur'evich Kulikov Evgenia Evgen'evna Arinina |
| author_sort | Ivan Ivanovich Dedov |
| collection | DOAJ |
| description | Aim. To carry out cost-effectiveness analysis of treatment options for type 2 diabetes using different groups of medicines, to prognosticate late diabeticcomplications and the cost of their management. Materials and methods. A total of 3678 DM2 patients (with mean HbAc1 level 9.3%) were examined in 23 regionsin the framework of the Diabetesmellitus subprogram of the Federal target program "Prevention and control of socially significant diseases". Two hypothetical therapeutic modalitieswere considered: treatment with NovoMix 30 and oral hypoglycemic (OHG) agents. The CORE model was used to analyse anticipated expendituresand DM outcomes. Results. Simulation revealed a greater decrease of HbA1c levels (-1.7%), reduction of total cholesterol, LDL, systolic AP (-4.1%) and risk of cardiovasculardiseases coupled to increase of HDL in patients treated with NovoMix 30. Maximum life expectancy was 17.2 yr compared with 16.5 yrin the OHG group and overall cost of the treatment 1,650,725 and 1,586,234 rubles respectively. Savings for the treatment of diabetes using NovoMix30 amounted to 19,832 rubles per patients due to reduced indirect expenditures including management of renal, cardiac, ophthalmologic , and cerebrovascularcomplications. Conclusion. Simulation of late results of DM2 treatment demonstrated enhanced pharmacoeconomic efficiency of modern insulin analogs comparedwith OHG agents. |
| first_indexed | 2024-03-08T15:22:19Z |
| format | Article |
| id | doaj.art-6244d694f989443796f5619c483ff780 |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2024-04-24T22:03:18Z |
| publishDate | 2010-03-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-6244d694f989443796f5619c483ff7802024-03-20T11:47:55ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782010-03-0113110111010.14341/2072-0351-60245982Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agentsIvan Ivanovich Dedov0Marina Vladimirovna Shestakova1Yury Ivanovich Suntsov2Roza Imailovna Yagudina3Ivan Sergeevich Krysanov4Andrey Yur'evich Kulikov5Evgenia Evgen'evna Arinina6Endocrinology Research Centre, MoscowEndocrinological Research Centre, MoscowEndocrinological Research Centre, MoscowI.M. Sechenov Moscow Medical Academy, MoscowI.M. Sechenov Moscow Medical Academy, MoscowI.M. Sechenov Moscow Medical Academy, MoscowI.M. Sechenov Moscow Medical Academy, MoscowAim. To carry out cost-effectiveness analysis of treatment options for type 2 diabetes using different groups of medicines, to prognosticate late diabeticcomplications and the cost of their management. Materials and methods. A total of 3678 DM2 patients (with mean HbAc1 level 9.3%) were examined in 23 regionsin the framework of the Diabetesmellitus subprogram of the Federal target program "Prevention and control of socially significant diseases". Two hypothetical therapeutic modalitieswere considered: treatment with NovoMix 30 and oral hypoglycemic (OHG) agents. The CORE model was used to analyse anticipated expendituresand DM outcomes. Results. Simulation revealed a greater decrease of HbA1c levels (-1.7%), reduction of total cholesterol, LDL, systolic AP (-4.1%) and risk of cardiovasculardiseases coupled to increase of HDL in patients treated with NovoMix 30. Maximum life expectancy was 17.2 yr compared with 16.5 yrin the OHG group and overall cost of the treatment 1,650,725 and 1,586,234 rubles respectively. Savings for the treatment of diabetes using NovoMix30 amounted to 19,832 rubles per patients due to reduced indirect expenditures including management of renal, cardiac, ophthalmologic , and cerebrovascularcomplications. Conclusion. Simulation of late results of DM2 treatment demonstrated enhanced pharmacoeconomic efficiency of modern insulin analogs comparedwith OHG agents.https://www.dia-endojournals.ru/jour/article/view/6024simulationpharmacoeconomiccostinsulin analogsoral agents |
| spellingShingle | Ivan Ivanovich Dedov Marina Vladimirovna Shestakova Yury Ivanovich Suntsov Roza Imailovna Yagudina Ivan Sergeevich Krysanov Andrey Yur'evich Kulikov Evgenia Evgen'evna Arinina Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents Сахарный диабет simulation pharmacoeconomic cost insulin analogs oral agents |
| title | Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents |
| title_full | Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents |
| title_fullStr | Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents |
| title_full_unstemmed | Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents |
| title_short | Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents |
| title_sort | pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents |
| topic | simulation pharmacoeconomic cost insulin analogs oral agents |
| url | https://www.dia-endojournals.ru/jour/article/view/6024 |
| work_keys_str_mv | AT ivanivanovichdedov pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents AT marinavladimirovnashestakova pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents AT yuryivanovichsuntsov pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents AT rozaimailovnayagudina pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents AT ivansergeevichkrysanov pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents AT andreyyurevichkulikov pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents AT evgeniaevgenevnaarinina pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents |